Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

Abhishek Maiti, Jorge E. Cortes, Yolanda D. Brown, Hagop M. Kantarjian

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)722-725
Number of pages4
JournalLeukemia and Lymphoma
Volume58
Issue number3
DOIs
StatePublished - Mar 4 2017
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this